Imperatorin ameliorates metabolic dysfunction‐associated fatty liver disease through modulating Suv39h1/Fabps/Cept1 signalling pathway
Authors
- Huijun Sun (ORCID: https://orcid.org/0000-0003-4474-6966)
- Ruyi Hao (ORCID: https://orcid.org/0009-0003-9736-7377)
- Yang Wang (ORCID: https://orcid.org/0009-0006-9220-2188)
- Changyuan Wang (ORCID: https://orcid.org/0000-0002-5669-1483)
- Yue Jin (ORCID: https://orcid.org/0000-0002-0426-5933)
- Yi Sun
- Lu Liu (ORCID: https://orcid.org/0009-0008-7393-4329)
Institutions
- Dalian Medical University (CN)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1111/bph.70210
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00